WO1994026293B1 - Facilitation immunologique par une therapie intermittente a l'interleukine-2 - Google Patents
Facilitation immunologique par une therapie intermittente a l'interleukine-2Info
- Publication number
- WO1994026293B1 WO1994026293B1 PCT/US1994/005397 US9405397W WO9426293B1 WO 1994026293 B1 WO1994026293 B1 WO 1994026293B1 US 9405397 W US9405397 W US 9405397W WO 9426293 B1 WO9426293 B1 WO 9426293B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- administrations
- period
- therapy
- amount
- Prior art date
Links
- 102000000588 Interleukin-2 Human genes 0.000 title claims abstract 21
- 108010002350 Interleukin-2 Proteins 0.000 title claims abstract 21
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract 11
- 230000001900 immune effect Effects 0.000 title claims 5
- 210000000987 Immune System Anatomy 0.000 claims abstract 6
- 201000010099 disease Diseases 0.000 claims abstract 6
- 210000001744 T-Lymphocytes Anatomy 0.000 claims abstract 5
- 230000001177 retroviral Effects 0.000 claims abstract 5
- 230000000798 anti-retroviral Effects 0.000 claims abstract 4
- 210000004698 Lymphocytes Anatomy 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 3
- 238000011065 in-situ storage Methods 0.000 claims abstract 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract 2
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims abstract 2
- 229960002555 Zidovudine Drugs 0.000 claims abstract 2
- 230000003213 activating Effects 0.000 claims abstract 2
- 230000035492 administration Effects 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 201000009910 diseases by infectious agent Diseases 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 230000000051 modifying Effects 0.000 claims 3
- 239000007929 subcutaneous injection Substances 0.000 claims 3
- 230000001419 dependent Effects 0.000 claims 2
- 230000001717 pathogenic Effects 0.000 claims 2
- 244000052769 pathogens Species 0.000 claims 2
- 230000001131 transforming Effects 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 210000004027 cells Anatomy 0.000 abstract 2
- 230000026683 transduction Effects 0.000 abstract 2
- 238000010361 transduction Methods 0.000 abstract 2
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000002459 sustained Effects 0.000 abstract 1
Abstract
Un procédé d'activation du système immunitaire d'un mammifère selon l'invention suppose une série de perfusions d'IL-2 continues effectuées par intermittence sur une période prolongée. On peut, par exemple, administrer l'IL-2 en continu sur une période de l'ordre de 5 jours, et entrecouper les perfusions successives de ce type d'une période d'au moins 4 semaines. On obtient des effets bénéfiques durables tels qu'une numération cellulaire de CD4 élevée, le rétablissement de la fonction lymphocytaire et l'augmentation du nombre des récepteurs de l'IL-2 grâce à cette thérapie intermittente à l'IL-2 qui peut également être combinée avec une autre thérapie dirigée contre un état pathologique spécifique telle que la thérapie antirétrovirale qui consiste, par exemple, en l'administration d'AZT, de ddI ou d'interféron alpha. On peut, de plus, administrer l'IL-2 pour faciliter la transduction in situ de lymphocytes T dans le contexte d'une thérapie génique. Ainsi, on active d'abord les cellules in vivo par la thérapie susmentionnée, et on procède à la transduction par administration directe d'un vecteur rétroviral manipulé génétiquement au patient.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE69428992T DE69428992T2 (de) | 1993-05-19 | 1994-05-19 | Immunologische verbesserung mit intermittierender interleukin-2 therapie |
| AT94920673T ATE208206T1 (de) | 1993-05-19 | 1994-05-19 | Immunologische verbesserung mit intermittierender interleukin-2 therapie |
| AU71377/94A AU691504B2 (en) | 1993-05-19 | 1994-05-19 | Immunologic enhancement with intermittent interleukin-2 therapy |
| EP94920673A EP0702560B1 (fr) | 1993-05-19 | 1994-05-19 | Facilitation immunologique par une therapie intermittente a l'interleukine-2 |
| DK94920673T DK0702560T3 (da) | 1993-05-19 | 1994-05-19 | Immunforstærkning ved intermitterende interleukin-2 behandling |
| JP52574694A JP4275193B2 (ja) | 1993-05-19 | 1994-05-19 | 断続的なインターロイキン−２療法による免疫強化 |
| US08/452,440 US5696079A (en) | 1993-05-19 | 1995-05-26 | Immunologic enhancement with intermittent interleukin-2 therapy |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/063,315 US5419900A (en) | 1993-05-19 | 1993-05-19 | Immunologic enhancement with intermittent interleukin-2 therapy |
| US08/063,315 | 1993-05-19 |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/063,315 Continuation US5419900A (en) | 1993-05-19 | 1993-05-19 | Immunologic enhancement with intermittent interleukin-2 therapy |
| US08/063,315 Continuation-In-Part US5419900A (en) | 1993-05-19 | 1993-05-19 | Immunologic enhancement with intermittent interleukin-2 therapy |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US48707595A Continuation | 1993-05-19 | 1995-06-07 | |
| US48707595A Continuation-In-Part | 1993-05-19 | 1995-06-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994026293A1 WO1994026293A1 (fr) | 1994-11-24 |
| WO1994026293B1 true WO1994026293B1 (fr) | 1995-01-26 |
Family
ID=22048393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1994/005397 WO1994026293A1 (fr) | 1993-05-19 | 1994-05-19 | Facilitation immunologique par une therapie intermittente a l'interleukine-2 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US5419900A (fr) |
| EP (1) | EP0702560B1 (fr) |
| JP (1) | JP4275193B2 (fr) |
| AT (1) | ATE208206T1 (fr) |
| AU (1) | AU691504B2 (fr) |
| CA (1) | CA2163219A1 (fr) |
| DE (1) | DE69428992T2 (fr) |
| DK (1) | DK0702560T3 (fr) |
| ES (1) | ES2167370T3 (fr) |
| PT (1) | PT702560E (fr) |
| WO (1) | WO1994026293A1 (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696079A (en) * | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
| US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
| US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
| JP2002515730A (ja) * | 1995-10-16 | 2002-05-28 | カイロン コーポレイション | 遺伝子発現を変調する因子のスクリーニング方法 |
| KR100220645B1 (ko) * | 1997-07-04 | 1999-09-15 | 구광시 | 벤젠유도체의 제조방법 |
| CA2310805A1 (fr) * | 1997-11-24 | 1999-06-03 | Johnson T. Wong | Procedes de traitement des infections par le vih ou autres infections utilisant un activateur de lymphocytes t ou un activateur viral et therapie d'association anti-retrovirale |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| WO2000039303A2 (fr) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Polypeptides vih env modifies |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| EP1141313A2 (fr) * | 1998-12-31 | 2001-10-10 | Chiron Corporation | Expression amelioree de polypeptides hiv et production de particules de type viral |
| US6921530B1 (en) * | 1999-09-24 | 2005-07-26 | Cornell Research Foundation, Inc. | Low dose IL-2 for potentiation of immunity |
| FR2813793B1 (fr) * | 2000-09-08 | 2003-01-24 | Aventis Pasteur | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ |
| EP1317281A1 (fr) * | 2000-09-08 | 2003-06-11 | Aventis Pasteur | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ |
| US6579521B2 (en) * | 2000-10-20 | 2003-06-17 | Chiron Corporation | Methods of therapy for HIV infection |
| US20030003074A1 (en) * | 2001-06-14 | 2003-01-02 | Macromed, Inc. | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
| US20060159657A1 (en) * | 2001-06-14 | 2006-07-20 | Macromed, Incorporated | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
| AU2002320314A1 (en) * | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| EP2292772A1 (fr) * | 2001-07-05 | 2011-03-09 | Novartis Vaccines and Diagnostics, Inc. | Vaccination VIH avec un ADN codant un polypeptide VIH et un polypeptide VIH |
| US7371371B2 (en) * | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| WO2003020876A2 (fr) * | 2001-08-31 | 2003-03-13 | Chiron Corporation | Polynucleotides codant des polypeptides de type b du vih antigeniques, polypeptides et leurs utilisations |
| US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| RU2201762C1 (ru) * | 2001-10-09 | 2003-04-10 | Свадовский Александр Игоревич | Способ лечения внутримозговой опухоли головного мозга |
| EP1676132B1 (fr) | 2003-10-21 | 2014-01-22 | Cedars-Sinai Medical Center | La combinaison de la chimiothérapie et de l'administration de cellules dendritiques pulsée avev gliome antigènes dans le traitement du gliome |
| US20070098685A1 (en) * | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
| US8129184B2 (en) | 2006-09-26 | 2012-03-06 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| CA2700436C (fr) | 2006-09-28 | 2017-04-18 | John S. Yu | Vaccins contre le cancer et methodes de vaccination |
| DK2328923T3 (en) | 2008-09-02 | 2016-03-21 | Cedars Sinai Medical Center | CD133 epitopes |
| PT2427485T (pt) | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | Epitopos cd133 |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| WO2013169691A1 (fr) | 2012-05-07 | 2013-11-14 | Trustees Of Dartmouth College | Anticorps anti-b7-h6, protéines de fusion, et leurs procédés d'utilisation |
| WO2014127296A1 (fr) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd | Vaccins contre le cancer et méthodes de vaccination |
| WO2016057651A1 (fr) | 2014-10-09 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Schéma posologique d'il-2 variables multiples pour le traitement de troubles immunitaires |
| IL294659A (en) | 2020-01-14 | 2022-09-01 | Synthekine Inc | Methods and preparations of il2 skewed mutants |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
| US4863730A (en) | 1986-03-21 | 1989-09-05 | Cenfold Holdings, S.A. | Immunotherapy for AIDS patients |
| US4868157A (en) | 1987-10-05 | 1989-09-19 | Merck & Co., Inc. | Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use |
| US4866157A (en) * | 1987-11-10 | 1989-09-12 | Sugio Otani | Thermosetting aromatic resin composition |
| DE3818054C2 (de) * | 1988-05-27 | 1994-02-17 | Biotest Pharma Gmbh | Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen |
| FR2653020B1 (fr) * | 1989-10-17 | 1993-03-26 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies. |
| US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
| EP0513161B1 (fr) | 1990-01-26 | 1995-04-05 | Washington Research Foundation | Reactivite immune envers des oncogenes exprimes actives pour le diagnostic et le traitement de malignites |
| FR2660863B1 (fr) * | 1990-04-17 | 1994-01-21 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre. |
| US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
| US5696079A (en) | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
-
1993
- 1993-05-19 US US08/063,315 patent/US5419900A/en not_active Expired - Lifetime
-
1994
- 1994-05-19 DK DK94920673T patent/DK0702560T3/da active
- 1994-05-19 ES ES94920673T patent/ES2167370T3/es not_active Expired - Lifetime
- 1994-05-19 JP JP52574694A patent/JP4275193B2/ja not_active Expired - Lifetime
- 1994-05-19 CA CA002163219A patent/CA2163219A1/fr not_active Withdrawn
- 1994-05-19 WO PCT/US1994/005397 patent/WO1994026293A1/fr active IP Right Grant
- 1994-05-19 AU AU71377/94A patent/AU691504B2/en not_active Expired
- 1994-05-19 PT PT94920673T patent/PT702560E/pt unknown
- 1994-05-19 AT AT94920673T patent/ATE208206T1/de active
- 1994-05-19 EP EP94920673A patent/EP0702560B1/fr not_active Expired - Lifetime
- 1994-05-19 DE DE69428992T patent/DE69428992T2/de not_active Expired - Lifetime
-
1997
- 1997-09-02 US US08/922,218 patent/US6190656B1/en not_active Expired - Lifetime
-
2000
- 2000-08-09 US US09/635,286 patent/US6548055B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1994026293B1 (fr) | Facilitation immunologique par une therapie intermittente a l'interleukine-2 | |
| US4791101A (en) | Synergistic mixtures of interferons and tumor necrosis factor | |
| Cameron et al. | Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases | |
| CA2114014A1 (fr) | Systeme d'administration de medicament et methode pour traiter a l'aide de la carbamazepine les troubles psychiatriques, neurologiques et autres | |
| EP0445228A1 (fr) | Immunotherapie mettant en uvre la stimulation de la cd28 | |
| AU640954B2 (en) | Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or H2-receptor agonists | |
| Bernard et al. | Transient focal neurologic deficits complicating interleukin‐2 therapy | |
| EP0303687B1 (fr) | Compositions pour ameliorer les therapies adcc | |
| EP1450850B1 (fr) | Methode d'administration d'un peptide alpha 1 de la thymosine | |
| WO1994013314A1 (fr) | Traitement combine des infections a vih mettant en oeuvre la thymosine, l'interleukine et des inhibiteurs de replication du vih ou de transcriptase reverse | |
| AU2002363248A1 (en) | Method of administering a Thymosin alpha 1 peptide | |
| US20020035998A1 (en) | Method for treatment of cancer and infectious disease | |
| Fujiwara et al. | Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet | |
| BR9809159A (pt) | Composição farmacêutica contendo uscaridina ou seus análogos | |
| KR900701301A (ko) | 후천성 면역 결핍증과 연관된 골수억제증의 치료방법 | |
| Asano et al. | Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma | |
| CA2228379A1 (fr) | Utilisation combinee d'interleukine-10 et de cyclosporine pour une therapie immunosuppressive | |
| Galvani et al. | Endolymphatic delivery of IL2 in patients with melanoma and lymphoma | |
| EP0561927B1 (fr) | Compositions pharmaceutiques destinees au traitement des affections malignes a lymphocytes b | |
| østensen et al. | Modulation of human natural killer cell function by cytokines and rheumatic disease | |
| Brenner | Interleukin 2 and the treatment of leukemia and lymphoma | |
| Kapás et al. | Hypnogenic effects of interleukin-1β (IL-1β) persist in diabetic rats | |
| Kapás et al. | Somnogenic and pyrogenic activity of TNFα, TNFβ and fragments of TNFα | |
| AU2008200190A1 (en) | Method of Administering a Thymosin Alpha 1 Peptide | |
| Joseph et al. | Down regulation of IFN-gamma induced class II expression on human glioma cells by recombinant beta interferon |